Diagnosis & Tests

for Bone Cancer

When diagnosed with bone cancer further tests are necessary to determine the extent of spread (stage) of the cancer. Cancer’s stage is a key factor in determining the best treatment. In addition to a physical examination, bone cancer may be evaluated by the use of either radiological tests, surgical biopsy, or blood tests.

Radiological Tests

Radiological tests, including X-ray, bone scan, and skeletal survey, remain the best method for evaluating cancer in the bones.

X-ray: When a patient experiences pain that is suspected to be a result of bone cancer, the first step in diagnosis is usually to X-ray the area near the pain. When enough of the healthy bone in any area is worn away by metastatic lesions, the damaged area will show up as a dark spot on the X-ray that look like holes in the bones.

Bone Scan: A bone scan is used to determine whether cancer has spread to the bones. Prior to a bone scan a small amount of radioactive substance is injected into a vein. This substance travels through the bloodstream and collects in areas of abnormal bone growth. An instrument called a scanner measures the radioactivity levels in these areas and records them on x-ray film.

Skeletal Survey: In order to diagnose blastic lesions, or lesions where extra bone has built up, a skeletal survey may be utilized. This is a form of X-ray. Normally an X-ray is selective for a particular area of concern, but with a skeletal survey, all areas are imaged. All patients with multiple myeloma and many with breast cancer undergo a skeletal survey to detect bone metastases that have not yet developed observable symptoms.

Other: Occasionally, other radiological procedures may be used to assess bone cancer, such as a computed axial tomography (CAT) scan, magnetic resonance imaging (MRI) scan, or PET scan.

  • Computed Tomography (CT) Scan: A CT scan is a technique for imaging body tissues and organs, during which X-ray transmissions are converted to detailed images, using a computer to synthesize X-ray data. A CT scan is conducted with a large machine positioned outside the body that can rotate to capture detailed images of the organs and tissues inside the body.
  • Magnetic Resonance Imaging (MRI): MRI uses a magnetic field rather than X-rays, and can often distinguish more accurately between healthy and diseased tissue than a CT. An MRI gives a better picture of cancer located near bone than does CT, does not use radiation, and provides pictures from various angles that enable doctors to construct a three-dimensional image of the cancer.
  • Positron emission tomography (PET): Positron emission tomography scanning is an advanced technique for imaging body tissues and organs. One characteristic of living tissue is the metabolism of sugar. Prior to a PET scan, a substance containing a type of sugar attached to a radioactive isotope (a molecule that emits radiation) is injected into the patient’s vein. The cancer cells “take up” the sugar and attached isotope, which emits positively charged, low energy radiation (positrons) that create the production of gamma rays that can be detected by the PET machine to produce a picture. If no gamma rays are detected in the scanned area, it is unlikely that the mass in question contains living cancer cells.

Surgical Biopsy

Either a needle biopsy or an incisional biopsy may also be useful for diagnosing bone cancer. During a needle biopsy, the surgeon makes a small hole in the bone and removes a sample of tissue from the tumor with a needle-like instrument. In an incisional biopsy, the surgeon cuts into the tumor and removes a sample of tissue. The tissue is then examined under a microscope to determine whether it is cancerous. Biopsies are best done by orthopedic oncologists—doctors experienced in the diagnosis of cancer involving the bone.

Blood Tests

The early detection of bone cancer is important for effective management. In the past, pain and fractures were often the first signs of cancer involving bones. Unfortunately, by the time these signs occur, the cancer cells are already present and have begun to impact the patients overall bone health. Relying on these signs typically results in a late diagnosis of bone cancer. Blood tests that can detect the presence of bone cancers before they manifest in pain or fractures may be useful for identifying patients that would benefit from treatment before complications develop.

Cancers in the bone cause an increase in bone remodeling activity. Normal bone is constantly being remodeled, or broken down and rebuilt. Cancer cells disrupt the balance between the activity of osteoclasts (cells that break down bone) and osteoblasts (cells that build bone). When cancer cells are in the bones, some proteins, genes, or byproducts from the building blocks of bone are produced at a higher rate than during normal remodeling.

Measuring blood levels of these substances, called biological markers, can be useful for diagnosing cancer involving the bones. Higher levels can indicate that a cancer has progressed. Though most biological markers are not routinely used for the diagnosis of bone cancers at this time, some are very useful, while others show promise for the future.

Bone specific alkaline phosphatase (BSAP) is an enzyme that is present in the cells that participate in bone formation, called osteoblasts. BSAP has been used for many years to detect increases in bone formation activity. Blood levels of BSAP are increased in patients with bone cancer and other conditions that result in increased bone remodeling. Increases in BSAP have been detected in patients with bone metastasis caused by prostate cancer, and to a lesser degree, in bone metastases from breast cancer. Unfortunately, BSAP is not completely specific for cancer because alkaline phosphatases are also produced by other organs and can be elevated by other conditions. Nonetheless, BSAP can be monitored in patients who are known to be at risk of bone metastases.

Other biochemical markers are under investigation, but at this time, none have been approved for use in the clinical setting.

Genomic or Biomarker Testing-Precision Cancer Medicine

The purpose of precision cancer medicine is to define the genomic alterations in the cancers DNA that are driving that specific cancer. Precision cancer medicine utilizes molecular diagnostic & genomic testing, including DNA sequencing, to identify cancer-driving abnormalities in a cancer’s genome. Once a genetic abnormality is identified, a specific targeted therapy can be designed to attack a specific mutation or other cancer-related change in the DNA programming of the cancer cells. Precision cancer medicine uses targeted drugs and immunotherapies engineered to directly attack the cancer cells with specific abnormalities, leaving normal cells largely unharmed.

By testing a cancer for specific unique biomarkers doctors can offer the most personalized treatment approach utilizing precision medicines.

Learn more here: http://oncoprecision.org/

Learn more about the following:

References


American Cancer Society. Cancer Facts & Figures 2016.

National Cancer Institute Fact Sheet. Human Papillomaviruses and Cancer: Questions and Answers.